JP2008527002A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008527002A5 JP2008527002A5 JP2007551449A JP2007551449A JP2008527002A5 JP 2008527002 A5 JP2008527002 A5 JP 2008527002A5 JP 2007551449 A JP2007551449 A JP 2007551449A JP 2007551449 A JP2007551449 A JP 2007551449A JP 2008527002 A5 JP2008527002 A5 JP 2008527002A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- disease
- activating compound
- sirtuin activating
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 56
- 108050002485 Sirtuin Proteins 0.000 claims 26
- 102000011990 Sirtuin Human genes 0.000 claims 26
- 230000003213 activating effect Effects 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 23
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims 12
- AYMYWHCQALZEGT-ORCRQEGFSA-N butein Chemical compound OC1=CC(O)=CC=C1C(=O)\C=C\C1=CC=C(O)C(O)=C1 AYMYWHCQALZEGT-ORCRQEGFSA-N 0.000 claims 12
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 claims 12
- 239000000126 substance Substances 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 10
- 208000023105 Huntington disease Diseases 0.000 claims 9
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims 9
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims 9
- 229940016667 resveratrol Drugs 0.000 claims 9
- 235000021283 resveratrol Nutrition 0.000 claims 9
- 208000024827 Alzheimer disease Diseases 0.000 claims 8
- 208000018737 Parkinson disease Diseases 0.000 claims 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 8
- 201000006417 multiple sclerosis Diseases 0.000 claims 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims 8
- IIXHQGSINFQLRR-UHFFFAOYSA-N Piceatannol Natural products Oc1ccc(C=Cc2c(O)c(O)c3CCCCc3c2O)cc1O IIXHQGSINFQLRR-UHFFFAOYSA-N 0.000 claims 6
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims 6
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 235000011990 fisetin Nutrition 0.000 claims 6
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims 6
- CDRPUGZCRXZLFL-OWOJBTEDSA-N piceatannol Chemical compound OC1=CC(O)=CC(\C=C\C=2C=C(O)C(O)=CC=2)=C1 CDRPUGZCRXZLFL-OWOJBTEDSA-N 0.000 claims 6
- 235000005875 quercetin Nutrition 0.000 claims 6
- 229960001285 quercetin Drugs 0.000 claims 6
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 4
- 230000002438 mitochondrial effect Effects 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 206010008748 Chorea Diseases 0.000 claims 3
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 3
- 102000003964 Histone deacetylase Human genes 0.000 claims 3
- 108090000353 Histone deacetylase Proteins 0.000 claims 3
- 208000009829 Lewy Body Disease Diseases 0.000 claims 3
- 229940122054 Peroxisome proliferator-activated receptor delta agonist Drugs 0.000 claims 3
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims 3
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims 3
- 208000012601 choreatic disease Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 210000003743 erythrocyte Anatomy 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 230000000302 ischemic effect Effects 0.000 claims 3
- 201000010901 lateral sclerosis Diseases 0.000 claims 3
- 208000005264 motor neuron disease Diseases 0.000 claims 3
- 108010040003 polyglutamine Proteins 0.000 claims 3
- 229920000155 polyglutamine Polymers 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims 2
- 229940126033 PPAR agonist Drugs 0.000 claims 2
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 229940122803 Vinca alkaloid Drugs 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 210000002569 neuron Anatomy 0.000 claims 2
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 claims 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 2
- 229960000237 vorinostat Drugs 0.000 claims 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical group C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 claims 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims 1
- 102000007371 Ataxin-3 Human genes 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 1
- RNTJDJDUXWVMJY-UHFFFAOYSA-N CC(C)(OC(=O)C(=O)c1ccc(O)cc1)C1Cc2cc3ccc(=O)oc3cc2O1 Chemical compound CC(C)(OC(=O)C(=O)c1ccc(O)cc1)C1Cc2cc3ccc(=O)oc3cc2O1 RNTJDJDUXWVMJY-UHFFFAOYSA-N 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 108010069514 Cyclic Peptides Proteins 0.000 claims 1
- 102000001189 Cyclic Peptides Human genes 0.000 claims 1
- 108010002156 Depsipeptides Proteins 0.000 claims 1
- DLVJMFOLJOOWFS-UHFFFAOYSA-N Depudecin Natural products CC(O)C1OC1C=CC1C(C(O)C=C)O1 DLVJMFOLJOOWFS-UHFFFAOYSA-N 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 1
- 208000027747 Kennedy disease Diseases 0.000 claims 1
- PTJGLFIIZFVFJV-UHFFFAOYSA-N N'-hydroxy-N-(3-pyridinyl)octanediamide Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CN=C1 PTJGLFIIZFVFJV-UHFFFAOYSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 102000023984 PPAR alpha Human genes 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims 1
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 1
- 201000003620 Spinocerebellar ataxia type 6 Diseases 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000002555 anti-neurodegenerative effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 210000003591 cerebellar nuclei Anatomy 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- DLVJMFOLJOOWFS-INMLLLKOSA-N depudecin Chemical compound C[C@@H](O)[C@@H]1O[C@H]1\C=C\[C@H]1[C@H]([C@H](O)C=C)O1 DLVJMFOLJOOWFS-INMLLLKOSA-N 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 230000001898 pallidal effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 1
- 210000000463 red nucleus Anatomy 0.000 claims 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims 1
- 150000004666 short chain fatty acids Chemical class 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 claims 1
- 201000003570 spinocerebellar ataxia type 17 Diseases 0.000 claims 1
- 201000003632 spinocerebellar ataxia type 7 Diseases 0.000 claims 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 210000003934 vacuole Anatomy 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- 229960004355 vindesine Drugs 0.000 claims 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64392105P | 2005-01-13 | 2005-01-13 | |
| US66717905P | 2005-03-30 | 2005-03-30 | |
| US69278505P | 2005-06-22 | 2005-06-22 | |
| US73652805P | 2005-11-14 | 2005-11-14 | |
| US75360605P | 2005-12-23 | 2005-12-23 | |
| PCT/US2006/001428 WO2006076681A2 (en) | 2005-01-13 | 2006-01-13 | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012274969A Division JP2013082723A (ja) | 2005-01-13 | 2012-12-17 | 神経変性障害および血液凝固障害を予防および処置するための新規組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008527002A JP2008527002A (ja) | 2008-07-24 |
| JP2008527002A5 true JP2008527002A5 (https=) | 2009-02-19 |
Family
ID=36678263
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007551449A Withdrawn JP2008527002A (ja) | 2005-01-13 | 2006-01-13 | 神経変性障害および血液凝固障害を予防および処置するための新規組成物 |
| JP2012274969A Withdrawn JP2013082723A (ja) | 2005-01-13 | 2012-12-17 | 神経変性障害および血液凝固障害を予防および処置するための新規組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012274969A Withdrawn JP2013082723A (ja) | 2005-01-13 | 2012-12-17 | 神経変性障害および血液凝固障害を予防および処置するための新規組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20060276393A1 (https=) |
| EP (1) | EP1850840A2 (https=) |
| JP (2) | JP2008527002A (https=) |
| AU (1) | AU2006204699B2 (https=) |
| CA (1) | CA2595159A1 (https=) |
| WO (1) | WO2006076681A2 (https=) |
Families Citing this family (155)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040009601A1 (en) * | 2002-07-15 | 2004-01-15 | The Regents Of The University Of California | Methods for the regeneration and transformation of cotton |
| CA2529510A1 (en) | 2003-07-01 | 2005-01-13 | President And Fellows Of Harvard College | Compositions for manipulating the lifespan and stress response of cells and organisms |
| US20060025337A1 (en) * | 2003-07-01 | 2006-02-02 | President And Fellows Of Harvard College | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
| US20090169585A1 (en) * | 2003-10-23 | 2009-07-02 | Resveratrol Partners, Llc | Resveratrol-Containing Compositions And Their Use In Modulating Gene Product Concentration Or Activity |
| US20050158376A1 (en) * | 2003-10-23 | 2005-07-21 | Sardi William F. | Dietary supplement and method of processing same |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| EP1708689A2 (en) | 2003-12-29 | 2006-10-11 | The President and Fellows of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
| US7714161B2 (en) * | 2004-01-20 | 2010-05-11 | Brigham Young University | Sirtuin activating compounds and methods for making the same |
| US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
| CN102793972A (zh) | 2004-12-27 | 2012-11-28 | 范因斯坦医学研究院 | 通过电刺激迷走神经治疗炎症性疾病 |
| US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
| AU2006218403A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
| US20070014833A1 (en) * | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| US20060229265A1 (en) * | 2005-03-30 | 2006-10-12 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
| ES2524922T3 (es) | 2005-05-10 | 2014-12-15 | Intermune, Inc. | Derivados de piridona para modular el sistema de proteína cinasa activada por estrés |
| US20060292099A1 (en) * | 2005-05-25 | 2006-12-28 | Michael Milburn | Treatment of eye disorders with sirtuin modulators |
| WO2006127987A2 (en) * | 2005-05-25 | 2006-11-30 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| WO2006138418A2 (en) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
| US20070149466A1 (en) * | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| WO2007008548A2 (en) * | 2005-07-07 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| US7960605B2 (en) * | 2006-03-17 | 2011-06-14 | BioMaker Pharmaceuticals, Inc. | Methods for testing for caloric restriction (CR) mimetics |
| WO2008011083A2 (en) | 2006-07-18 | 2008-01-24 | Cornell Research Foundation, Inc. | Compounds for enhancing arginase activity and methods of use thereof |
| WO2008011538A2 (en) | 2006-07-19 | 2008-01-24 | The Salk Institute For Biological Studies | Methods of using flavonoids to enhance memory |
| WO2008027379A2 (en) * | 2006-08-29 | 2008-03-06 | Sirtris Pharmaceuticals, Inc. | Indicators of sirtuin activity and methods of use thereof |
| US20100144885A1 (en) * | 2006-09-29 | 2010-06-10 | The Board Of Trustees Of The University Of Illinois | Histone acetyl transferase activators and histone deacetylase inhibitors in the treatment of alcoholism |
| AU2007314141A1 (en) * | 2006-10-30 | 2008-05-08 | Novogen Research Pty Ltd | Prevention and reversal of chemotherapy-induced peripheral neuropathy |
| WO2008058287A1 (en) * | 2006-11-10 | 2008-05-15 | Syndax Pharmaceuticals, Inc. | COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER |
| US20080249103A1 (en) * | 2006-11-15 | 2008-10-09 | Sirtris Pharmaceuticals, Inc. | Sirtuin polymorphisms and methods of use thereof |
| US8778986B1 (en) * | 2007-01-25 | 2014-07-15 | University Of South Florida | Treatment of glycogen synthase kinase-based disease |
| US8802638B1 (en) * | 2007-01-25 | 2014-08-12 | University Of South Florida | Flavonoid treatment of glycogen synthase kinase-based disease |
| CA2681110A1 (en) | 2007-03-14 | 2008-09-18 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazole diamines |
| US9884031B2 (en) * | 2007-05-09 | 2018-02-06 | The Trustees Of The University Of Pennsylvania | Use of HDAC inhibitors for treatment of cardiac rhythm disorders |
| WO2008138943A2 (en) * | 2007-05-14 | 2008-11-20 | Universite Libre De Bruxelles | Prophylactic and therapeutic use of sirtuin inhibitors in tnf-alpha mediated pathologies |
| WO2009015179A1 (en) * | 2007-07-23 | 2009-01-29 | Syndax Pharmaceuticals, Inc. | Novel compounds and methods of using them |
| WO2009018326A2 (en) * | 2007-07-31 | 2009-02-05 | Limerick Biopharma, Inc. | Soluble pyrone analogs methods and compositions |
| JP5337405B2 (ja) | 2007-09-17 | 2013-11-06 | ザ・ホスピタル・フォー・シック・チルドレン | ゴーシェ病の治療方法 |
| WO2009054994A2 (en) * | 2007-10-23 | 2009-04-30 | President And Fellows Of Harvard College | Sirt-3 related methods and compositions for mimicking exercise |
| WO2009067453A1 (en) * | 2007-11-19 | 2009-05-28 | Syndax Pharmaceuticals, Inc. | Combinations of hdac inhibitors and proteasome inhibitors |
| EP2259782A4 (en) * | 2008-03-03 | 2013-01-23 | Nad Life Pty Ltd | PHARMACEUTICAL FORMULATIONS OF RESVERATROL AND METHOD FOR THEIR USE IN THE TREATMENT OF CELL DISEASES |
| WO2009118338A2 (en) * | 2008-03-27 | 2009-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of a polyphenolic type compound for preventing or treating a polyglutamine expansion neurodegenerative disease |
| US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
| US9211409B2 (en) | 2008-03-31 | 2015-12-15 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of T-cell activity |
| KR20130097813A (ko) | 2008-04-21 | 2013-09-03 | 오토노미, 인코포레이티드 | 귀 질환 및 병태를 치료하기 위한 귀 조제물 |
| US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
| CA2726588C (en) | 2008-06-03 | 2019-04-16 | Karl Kossen | Compounds and methods for treating inflammatory and fibrotic disorders |
| ITBS20080120A1 (it) * | 2008-06-10 | 2009-12-11 | Uni Degli Studi Brescia | Composizione farmaceutica e suo uso |
| US8784870B2 (en) | 2008-07-21 | 2014-07-22 | Otonomy, Inc. | Controlled release compositions for modulating free-radical induced damage and methods of use thereof |
| KR20110071064A (ko) * | 2008-08-19 | 2011-06-28 | 크놉 뉴로사이언시스 인코포레이티드 | (ｒ)-프라미펙솔을 사용하는 조성물 및 방법 |
| WO2010031043A2 (en) * | 2008-09-15 | 2010-03-18 | Georgetown University | Reducing or preventing neuroinflammation or neurotoxicity |
| WO2010042841A1 (en) * | 2008-10-09 | 2010-04-15 | University Of North Texas Health Science Center | Combination therapies for the treatment of degenerative inflammatory conditions of the nervous system |
| WO2010056880A1 (en) * | 2008-11-12 | 2010-05-20 | The Trustees Of The University Of Pennsylvania | Utrophin promoter activity upregulation for the treatment of muscular dystrophy |
| ES2452484T3 (es) | 2008-11-18 | 2014-04-01 | Setpoint Medical Corporation | Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria |
| US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
| US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| US20120129923A1 (en) * | 2009-05-20 | 2012-05-24 | Nutracryst Therapeutics Private Limited | Pharmaceutical co-crystals of quercetin |
| WO2010144578A2 (en) | 2009-06-09 | 2010-12-16 | Setpoint Medical Corporation | Nerve cuff with pocket for leadless stimulator |
| PH12012500382A1 (en) | 2009-09-03 | 2012-10-22 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| WO2014169145A1 (en) | 2013-04-10 | 2014-10-16 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
| US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
| CN105126248B (zh) | 2009-12-23 | 2018-06-12 | 赛博恩特医疗器械公司 | 用于治疗慢性炎症的神经刺激设备和系统 |
| WO2011163241A2 (en) * | 2010-06-21 | 2011-12-29 | Georgetown University | Neuroprotective compounds |
| US20120058088A1 (en) * | 2010-06-28 | 2012-03-08 | Resveratrol Partners, Llc | Resveratrol-Containing Compositions And Methods Of Use |
| WO2012008549A1 (ja) | 2010-07-15 | 2012-01-19 | 武田薬品工業株式会社 | 複素環化合物 |
| US9499790B2 (en) | 2010-08-26 | 2016-11-22 | Kyoto University | Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells |
| RU2013114390A (ru) | 2010-08-31 | 2014-10-10 | СНУ Ар энд ДиБи ФАУНДЕЙШН | Применение фетального репрограммирования посредством ppar-дельта-агониста |
| WO2012066330A1 (en) | 2010-11-17 | 2012-05-24 | Heptares Therapeutics Limited | Compounds useful as a2a receptor inhibitors |
| CA2823753C (en) | 2011-01-05 | 2019-03-12 | Bioenergenix Llc | Heterocyclic compounds for the inhibition of pask |
| EP2678305A4 (en) * | 2011-02-25 | 2015-11-04 | Univ Johns Hopkins | CHALCONE DERIVATIVES AS NRF2 ACTIVATORS |
| KR101466700B1 (ko) * | 2011-02-28 | 2014-11-28 | 동아대학교 산학협력단 | Ｓｉｒ－ＦＯＸＯ 신호전달체계 활성인자를 포함하는 퇴행성 신경질환 치료용 조성물 |
| BR112013022147A2 (pt) | 2011-03-02 | 2017-04-25 | Bioenergenix | composto, composição farmacêutica, método de inibição da pask, método de tratamento de uma doença, método para alcançar um efeito em um paciente e método de tratamento de uma doença mediada pela pask |
| US8916561B2 (en) | 2011-03-02 | 2014-12-23 | Bioenergenix, Llc | Substituted quinoxaline compounds for the inhibition of PASK |
| EP2898923A3 (en) * | 2011-04-15 | 2015-10-07 | Nestec S.A. | Isoflavones for regulating sirtuin gene expression |
| EP2707094B1 (en) | 2011-05-09 | 2016-02-03 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| US12172017B2 (en) | 2011-05-09 | 2024-12-24 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| CA2847292A1 (en) * | 2011-06-29 | 2013-01-03 | The General Hospital Corporation | Compositions and methods for enhancing bioenergetic status in female germ cells |
| EP3345901A3 (en) * | 2011-06-29 | 2018-09-12 | President and Fellows of Harvard College | Small molecules as antiaging agents |
| CN102887925B (zh) * | 2011-07-21 | 2015-08-12 | 中国科学院兰州化学物理研究所 | 从河套大黄中提取土大黄苷的方法 |
| US10391096B2 (en) * | 2011-10-13 | 2019-08-27 | Quercegen Pharmaceuticals Llc | Method for treating thrombotic disorders using quercetin-containing compositions |
| WO2013074948A1 (en) | 2011-11-16 | 2013-05-23 | Resveratrol Partners, Llc | Compositions containing resveratrol and nucleotides |
| WO2013096816A1 (en) | 2011-12-22 | 2013-06-27 | Biogen Idec Ma Inc. | Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
| KR101996343B1 (ko) | 2012-01-27 | 2019-07-05 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 전능성 줄기세포의 심근분화 유도방법 |
| CN106063787A (zh) | 2012-02-03 | 2016-11-02 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
| JP5813576B2 (ja) * | 2012-05-22 | 2015-11-17 | アピオン・ジャパン有限会社 | サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| US20140107154A1 (en) * | 2012-10-12 | 2014-04-17 | Teva Pharmaceutical Industries, Ltd. | Laquinimod for reducing thalamic damage in multiple sclerosis |
| TWI485145B (zh) | 2012-10-26 | 2015-05-21 | 財團法人工業技術研究院 | Ｐ型有機半導體材料與光電元件 |
| CA2894992A1 (en) * | 2012-12-24 | 2014-07-03 | Ramot At Tel-Aviv University Ltd. | Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same |
| CN103073605B (zh) * | 2012-12-27 | 2015-07-08 | 成都普思生物科技有限公司 | 一种蒙花苷单体的分离纯化方法 |
| JP2016507538A (ja) * | 2013-02-07 | 2016-03-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 置換キノキサリン誘導体およびｍＧｌｕＲ４の正のアロステリックモジュレーターとしてのそれらの使用 |
| US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
| WO2014136519A1 (ja) | 2013-03-08 | 2014-09-12 | 国立大学法人京都大学 | Ｅｇｆ受容体阻害剤を含む多能性幹細胞の心筋分化促進剤 |
| US20140287021A1 (en) * | 2013-03-21 | 2014-09-25 | Panacea Pharmaceuticals | Treatment of chemotherapy-induced peripheral neuropathy |
| CN105392788B (zh) * | 2013-05-13 | 2018-10-23 | 葛兰素史密斯克莱有限责任公司 | 用作沉默调节蛋白调节剂的取代的桥连脲类似物 |
| KR101477407B1 (ko) * | 2013-07-10 | 2014-12-29 | 국민대학교산학협력단 | 4,4'-비스(2-벤즈옥사졸일)스틸벤의 제조방법 |
| US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
| EP3838271B1 (en) | 2013-07-12 | 2025-09-03 | Areteia Therapeutics, Inc. | Treating elevated levels of eosinophils and/or basophils |
| CA2921381A1 (en) | 2013-08-13 | 2015-02-19 | Knopp Biosciences Llc | Compositions and methods for treating chronic urticaria |
| ES2813674T3 (es) | 2013-08-13 | 2021-03-24 | Knopp Biosciences Llc | Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b |
| EP3038600B1 (en) * | 2013-08-27 | 2020-06-03 | Northeastern University | Nanoparticle drug delivery system and method of treating cancer and neurotrauma |
| FR3015287B1 (fr) | 2013-12-19 | 2016-12-23 | Inst Nat Sante Rech Med | Combinaison de bezafibrate et de resveratrol pour le traitement et la prevention des maladies impliquant un dysfonctionnement energetique des mitochondries. |
| MX382781B (es) | 2014-04-02 | 2025-03-13 | Intermune Inc | Piridinonas anti-fibroticas. |
| WO2015154192A1 (en) * | 2014-04-11 | 2015-10-15 | George Robertson | Use of a composition comprising a flavonol, a flavonoid, and a fatty acid in the treatment of oxidative injuries due to mitochondrial dysfunction |
| JP6608605B2 (ja) * | 2014-04-25 | 2019-11-20 | 森永製菓株式会社 | サーチュイン発現増強剤 |
| EA201692180A1 (ru) | 2014-04-29 | 2017-08-31 | Тева Фармасьютикал Индастриз Лтд. | Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации |
| EP3150705B1 (en) | 2014-05-30 | 2019-05-15 | Kyoto University | Method for inducing myocardial differentiation of pluripotent stem cells using low-molecular compound |
| WO2016037171A1 (en) * | 2014-09-05 | 2016-03-10 | The Cleveland Clinic Foundation | Flavonoid il-17a inhibitors |
| US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
| ITMI20141843A1 (it) | 2014-10-27 | 2016-04-27 | Giovannini Luca | Associazioni sinergiche stimolanti l¿espressione di sirtuina 1 |
| JP2016094406A (ja) * | 2014-11-06 | 2016-05-26 | 森永製菓株式会社 | アストロサイト分化誘導剤及びｇｆａｐ発現誘導剤 |
| WO2016100444A1 (en) * | 2014-12-16 | 2016-06-23 | University Of Florida Research Foundation, Inc. | Treatment of closed head injury and hemorrhagic stroke with hbed |
| US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
| JP6914858B2 (ja) | 2015-06-15 | 2021-08-04 | ラッシュ・ユニバーシティ・メディカル・センター | 脳由来のＰＰＡＲαリガンド |
| JP6930969B2 (ja) * | 2015-07-08 | 2021-09-01 | ギルローズ ファーマシューティカルズ，リミティド ライアビリティ カンパニー | 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療 |
| EP3337469A4 (en) * | 2015-08-20 | 2019-05-01 | Paul A. Knepper | COMPOSITION AND METHOD FOR INHIBITING THE THROMBOCYTE AGGREGATION |
| WO2017087685A1 (en) | 2015-11-20 | 2017-05-26 | The Regents Of The University Of California | Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery |
| US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
| US10314501B2 (en) | 2016-01-20 | 2019-06-11 | Setpoint Medical Corporation | Implantable microstimulators and inductive charging systems |
| CN108882885A (zh) | 2016-01-20 | 2018-11-23 | 赛博恩特医疗器械公司 | 迷走神经刺激的控制 |
| US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
| US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
| KR101922903B1 (ko) | 2016-03-11 | 2018-11-28 | 전북대학교산학협력단 | 항신경변성 천연물 소재의 스크리닝 방법 |
| JP7033789B2 (ja) | 2016-06-29 | 2022-03-11 | オトノミー，インク． | トリグリセリド耳用製剤とその使用 |
| WO2018187240A1 (en) * | 2017-04-03 | 2018-10-11 | The Regents Of The University Of California | Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery |
| US11173307B2 (en) | 2017-08-14 | 2021-11-16 | Setpoint Medical Corporation | Vagus nerve stimulation pre-screening test |
| US20190108912A1 (en) * | 2017-10-05 | 2019-04-11 | Iquity, Inc. | Methods for predicting or detecting disease |
| TWI644665B (zh) * | 2017-12-08 | 2018-12-21 | 衛生福利部國家中醫藥研究所 | Use of stilbene and benzofuran derivatives for the treatment of neurological diseases |
| US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
| CA3121235A1 (en) | 2018-11-30 | 2020-06-04 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for reducing major thrombotic events in cancer patients |
| WO2020144753A1 (ja) * | 2019-01-09 | 2020-07-16 | 公立大学法人大阪 | 神経変性疾患の予防又は治療薬 |
| JP2022081702A (ja) * | 2019-01-25 | 2022-06-01 | 第一三共株式会社 | ピラゾール化合物 |
| US20220401404A1 (en) * | 2019-02-05 | 2022-12-22 | The Regents Of The University Of California | Co-Administration Therapy to Prevent Neurodegeneration and Enhance Neuroprotection |
| US12343535B2 (en) | 2019-04-12 | 2025-07-01 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| GB201912760D0 (en) * | 2019-09-05 | 2019-10-23 | Healx Ltd | Treatment |
| CN111096830B (zh) * | 2019-12-28 | 2021-11-30 | 杭州电子科技大学 | 一种基于LightGBM的外骨骼步态预测方法 |
| AU2021207815B2 (en) | 2020-01-13 | 2026-03-26 | The Feinstein Institutes For Medical Research | Treating bleeding and bleeding disorders via high intensity focused ultrasound stimulation of the spleen |
| US20230110676A1 (en) * | 2020-02-25 | 2023-04-13 | Ergo-Health LLC | Method of Treating Diseases |
| US20230116276A1 (en) * | 2020-03-16 | 2023-04-13 | William B. Coe | Dietary supplement comprising aldehyde functional monoterpenoids |
| US11938324B2 (en) | 2020-05-21 | 2024-03-26 | The Feinstein Institutes For Medical Research | Systems and methods for vagus nerve stimulation |
| JP2024511616A (ja) * | 2021-03-25 | 2024-03-14 | ラモット アット テル アビブ ユニバーシティ， リミテッド | 活性依存性神経栄養因子（ａｃｔｉｖｉｔｙ ｄｅｐｅｎｄｅｎｔ ｎｅｕｒｏｔｒｏｐｈｉｃ ｆａｃｔｏｒ、ａｄｎｆ）ポリペプチドを含む組成物及び物品 |
| JP2022150176A (ja) * | 2021-03-26 | 2022-10-07 | 国立大学法人九州大学 | サーチュイン活性化剤、食品、および化粧品 |
| WO2022245878A1 (en) | 2021-05-17 | 2022-11-24 | Setpoint Medical Corporation | Neurostimulation parameter authentication and expiration system for neurostimulation |
| AU2022276190A1 (en) * | 2021-05-19 | 2024-01-18 | Quercis Pharma AG | Quercetin-containing compositions for use in treating amyotrophic lateral sclerosis |
| WO2023288044A1 (en) | 2021-07-16 | 2023-01-19 | Beth Israel Deaconess Medical Center, Inc. | Method for treating sickle cell disease using quercetin-containing compositions |
| WO2023064857A1 (en) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
| FI4426434T3 (fi) | 2021-11-02 | 2025-11-24 | Flare Therapeutics Inc | Pparg:n käänteisagonisteja ja niiden käyttöjä |
| WO2023086388A1 (en) * | 2021-11-09 | 2023-05-19 | YewSavin, Inc. | Compositions and methods for treating bleeding and bleeding disorders |
| US20250229086A1 (en) | 2022-01-20 | 2025-07-17 | Setpoint Medical Corporation | Treatment of inflammatory disorders |
| US11679078B1 (en) | 2022-03-08 | 2023-06-20 | EternaTear, Inc. | Ophthalmic formulations and related methods |
| US20250312307A1 (en) * | 2022-05-17 | 2025-10-09 | Société des Produits Nestlé S.A. | Compositions and methods using a combination of fisetin and quercetin for use in cartilage degeneration |
| JP2025516064A (ja) * | 2022-05-17 | 2025-05-26 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 細胞エネルギーのためのフィセチンとケルセチンとの組み合わせを使用する組成物及び方法 |
| JP7784085B2 (ja) * | 2022-07-22 | 2025-12-11 | 長崎県公立大学法人 | 認知機能改善用の組成物、それを含む食品、薬剤、組成物キット、及び、その組成物の製造方法 |
| CN115478105B (zh) * | 2022-08-25 | 2023-06-30 | 郑州大学第一附属医院 | Sirt4在肝缺血疾病治疗中的应用 |
| WO2024233598A1 (en) * | 2023-05-08 | 2024-11-14 | YewSavin, Inc. | Compositions and methods for treating bleeding and bleeding disorders |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2543550B1 (fr) * | 1983-04-01 | 1985-08-09 | Cortial | Nouveaux derives de la tetrahydroxy-3', 4',5,7 flavone, leur methode de preparation et leur emploi therapeutique |
| IL107642A0 (en) * | 1992-11-20 | 1994-02-27 | Amgen Inc | Progenitor b cell stimulating factor |
| US5589483A (en) * | 1994-12-21 | 1996-12-31 | Geron Corporation | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence |
| US6184248B1 (en) * | 1996-09-05 | 2001-02-06 | Robert K. K. Lee | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| WO1999021565A1 (en) * | 1997-10-24 | 1999-05-06 | Cornell Research Foundation, Inc. | Nutritional supplement for cerebral metabolic insufficiencies |
| AU4084599A (en) * | 1998-05-18 | 1999-12-06 | Oklahoma Medical Research Foundation | Resveratrol inhibition of myeloperoxidase |
| IT1302365B1 (it) * | 1998-10-09 | 2000-09-05 | Sigma Tau Healthscience Spa | Uso di carnitine e resveratrolo per produrre una composizione per laprevenzione o il trattamento terapeutico di alterazioni cerebrali |
| US6264995B1 (en) * | 1999-10-19 | 2001-07-24 | Thomas Newmark | Herbal composition for reducing inflammation and methods of using same |
| US20020049176A1 (en) * | 1999-11-10 | 2002-04-25 | Anderson Christen M. | Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery |
| US7452664B2 (en) * | 1999-12-15 | 2008-11-18 | Massachusetts Institute Of Technology | Methods for identifying agents which alter histone protein acetylation |
| IT1317034B1 (it) * | 2000-05-30 | 2003-05-26 | Istituto Di Medicina Speriment | Metodo di estrazione di prodotti ad attivita' farmaceutica da piantespermatofite, prodotti cosi' ottenuti e loro impiego in medicina, in |
| US6812248B2 (en) * | 2000-07-05 | 2004-11-02 | John Hopkins University School Of Medicine | Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes |
| US20020110604A1 (en) * | 2000-08-11 | 2002-08-15 | Ashni Naturaceuticals, Inc. | Composition exhibiting synergistic antioxidant activity |
| IT1320080B1 (it) * | 2000-10-25 | 2003-11-18 | Giuliani Spa | Composizione per uso farmaceutico o dietetico. |
| US20020173549A1 (en) * | 2000-11-08 | 2002-11-21 | Wurtman Richard J. | Compositions and methods for treatment of mild cognitive impairment |
| WO2004096256A1 (en) * | 2001-01-23 | 2004-11-11 | The United States Of America, As Represented By The Secretary Of The Navy | Methods for preventing and treating loss of balance function due to oxidative stress |
| US6387416B1 (en) * | 2001-04-05 | 2002-05-14 | Thomas Newmark | Anti-Inflammatory herbal composition and method of use |
| US6964969B2 (en) * | 2001-04-19 | 2005-11-15 | Mccleary Edward Larry | Composition and method for treating impaired or deteriorating neurological function |
| PT1390378E (pt) * | 2001-04-30 | 2009-07-23 | Trommsdorff Arzneimittel | Ésteres de uridina farmaceuticamente activos |
| NZ516366A (en) * | 2001-12-24 | 2004-07-30 | Enzo Nutraceuticals Ltd | Increased lifespan formulation using pine bark flavonoid extract |
| US20030199581A1 (en) * | 2002-03-13 | 2003-10-23 | Seligson Allen L. | Boswellin compositions enhanced with 3-beta-acetyl-11-keto-beta-boswellic acid ("AKBA") industrial manufacture and uses |
| WO2003103583A2 (en) * | 2002-06-10 | 2003-12-18 | Oklahoma Medical Research Foundation | A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system |
| DE10230961A1 (de) * | 2002-07-10 | 2004-02-12 | Lorenz, Peter, Dr. | Verwendung von Oxyresveratrol als Neuroprotektivum |
| US7977049B2 (en) * | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| DE60335743D1 (de) * | 2002-11-20 | 2011-02-24 | Neuronova Ab | Verbindungen und verfahren zur erhöhung der neurogenese |
| GB0305150D0 (en) * | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Use of therapeutic compounds |
| US20060025337A1 (en) * | 2003-07-01 | 2006-02-02 | President And Fellows Of Harvard College | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
| CA2529510A1 (en) * | 2003-07-01 | 2005-01-13 | President And Fellows Of Harvard College | Compositions for manipulating the lifespan and stress response of cells and organisms |
| US20050107338A1 (en) * | 2003-11-17 | 2005-05-19 | Seidman Michael D. | Nutritional supplement enhancing mitochondrial function |
| EP1708689A2 (en) * | 2003-12-29 | 2006-10-11 | The President and Fellows of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
| US8017634B2 (en) * | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| JP2008501343A (ja) * | 2004-06-04 | 2008-01-24 | ワシントン・ユニバーシティ | 神経障害を治療するための方法および組成物 |
| WO2006007411A2 (en) * | 2004-06-16 | 2006-01-19 | President And Fellows Of Harvard College | Methods and compositions for modulating bax-mediated apoptosis |
| US20060024385A1 (en) * | 2004-07-27 | 2006-02-02 | Pedersen Mark A | Metabolic capacity enhancing compositions and methods for use in a mammal |
| WO2006079021A2 (en) * | 2005-01-20 | 2006-07-27 | Sirtris Pharmaceuticals, Inc. | Use of sirtuin-activating compounds for treating flushing and drug induced weight gain |
| US20070014833A1 (en) * | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| US20060292099A1 (en) * | 2005-05-25 | 2006-12-28 | Michael Milburn | Treatment of eye disorders with sirtuin modulators |
| US7838503B2 (en) * | 2005-06-15 | 2010-11-23 | Children's Medical Center Corporation | Methods for extending the replicative lifespan of cells |
| US7855289B2 (en) * | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US8093401B2 (en) * | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| EP1910385B1 (en) * | 2005-08-04 | 2013-07-24 | Sirtris Pharmaceuticals, Inc. | Benzothiazoles and thiazolopyridines as sirtuin modulators |
| US8088928B2 (en) * | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
-
2006
- 2006-01-13 JP JP2007551449A patent/JP2008527002A/ja not_active Withdrawn
- 2006-01-13 CA CA002595159A patent/CA2595159A1/en not_active Abandoned
- 2006-01-13 EP EP06718495A patent/EP1850840A2/en not_active Ceased
- 2006-01-13 WO PCT/US2006/001428 patent/WO2006076681A2/en not_active Ceased
- 2006-01-13 US US11/332,056 patent/US20060276393A1/en not_active Abandoned
- 2006-01-13 AU AU2006204699A patent/AU2006204699B2/en not_active Ceased
-
2012
- 2012-12-17 JP JP2012274969A patent/JP2013082723A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008527002A5 (https=) | ||
| JP5547654B2 (ja) | 精神神経系障害の治療のための、医薬組成物並びにｄ−アミノ酸及び抗酸化物を利用する方法 | |
| CA2878462A1 (en) | Tetracycline compounds for treating neurodegenerative disorders | |
| US10858323B2 (en) | HDAC inhibitors for the treatment of diabetic peripheral neuropathy | |
| MA33467B1 (fr) | Promédicaments comprenant un conjugué insuline-lieur | |
| WO2012013728A1 (en) | Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use | |
| JP2010518122A5 (https=) | ||
| EA201490277A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| WO2006004658A3 (en) | Furanopyrimidines | |
| WO2012006474A2 (en) | Compounds and methods for inhibiting phosphate transport | |
| WO2014052935A2 (en) | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| Nóbrega et al. | Molecular mechanisms and cellular pathways implicated in Machado-Joseph disease pathogenesis | |
| Mishra et al. | Development of novel N-(6-methanesulfonyl-benzothiazol-2-yl)-3-(4-substituted-piperazin-1-yl)-propionamides with cholinesterase inhibition, anti-β-amyloid aggregation, neuroprotection and cognition enhancing properties for the therapy of Alzheimer's disease | |
| JP2012514032A (ja) | ベンゾアリールウレイド化合物、及びこれを含有する神経退行性脳疾患予防又は治療用組成物 | |
| US20210283092A1 (en) | Methods and uses of colchicine derivatives | |
| AU2019349438B2 (en) | Indane derivatives for use in the treatment of bacterial infection | |
| CN102088976A (zh) | 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品 | |
| CN111868043B (zh) | 新型苯磺酰基噁唑衍生物及其用途 | |
| US20210363181A1 (en) | Dopamine precursors | |
| JP2020515536A (ja) | フマル酸サリチル誘導体、並びにパーキンソン病及び他の神経変性疾患の治療におけるその用途 | |
| JP6907174B2 (ja) | アミロイド線維形成の抑制又は阻害剤 | |
| US12589090B2 (en) | Compounds and methods for the treatment of degenerative disorders | |
| US20250381157A1 (en) | Antimicrobial compounds | |
| Vishwakarma et al. | Histone deacetylase inhibitors: pharmacotherapeutic implications as epigenetic modifier |